Ireland
# |
Name |
Receivables |
Reported Date | Stock Price |
Change |
Price (30 days) | Country |
---|---|---|---|---|---|---|---|
1 |
USD 705.79 M
|
Dec. 31, 2023 | USD 122.96 | -0.16% |
|
Ireland |
|
2 |
USD 333.18 M
|
Dec. 31, 2023 | USD 28.50 | 0.53% |
|
Ireland |
|
3 |
USD 13.43 M
|
Dec. 31, 2023 | USD 8.05 | 2.94% |
|
Ireland |
|
4 |
USD 8.75 M
|
Dec. 31, 2023 | USD 4.34 | 1.19% |
|
Ireland |
|
5 |
USD 5.16 M
|
Dec. 31, 2023 | USD 12.67 | -3.50% |
|
Ireland |
|
6 |
USD 233.00 K
|
Dec. 31, 2023 | USD 1.60 | -2.44% |
|
Ireland |
|
7 |
USD 178.00 K
|
Dec. 31, 2023 | USD 8.19 | -1.92% |
|
Ireland |
The Biotechnology company in Ireland with the highest Receivables is Jazz Pharmaceuticals plc (NasdaqGS: JAZZ) at USD 705.79 M.
The Biotechnology company in Ireland with the lowest Receivables is GH Research PLC (NasdaqGM: GHRS) at USD 178.00 K.
The top 10 Biotechnology companies in Ireland by Receivables are Jazz Pharmaceuticals plc, Alkermes plc, Avadel Pharmaceuticals plc, kneat.com, inc., Prothena Corporation plc, Iterum Therapeutics plc and GH Research PLC.
The bottom 10 Biotechnology companies in Ireland by Receivables are GH Research PLC, Iterum Therapeutics plc, Prothena Corporation plc, kneat.com, inc., Avadel Pharmaceuticals plc, Alkermes plc and Jazz Pharmaceuticals plc.